Cargando…
Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease
INTRODUCTION: End‐stage renal disease (ESRD) is associated with increased infectious susceptibility and with reduced vaccine responses consistent with compromised humoral immunity. Whether the compromised humoral immunity is due to reduced antibody diversity (reduced somatic hypermutation [SHM]) or...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879468/ https://www.ncbi.nlm.nih.gov/pubmed/27957330 http://dx.doi.org/10.1002/iid3.108 |
_version_ | 1782433676415467520 |
---|---|
author | Assing, Kristian Nielsen, Christian Jakobsen, Marianne Scholze, Alexandra Nybo, Mads Soerensen, Grete Mortensen, Sussie Vejen, Knud Barington, Torben Bistrup, Claus |
author_facet | Assing, Kristian Nielsen, Christian Jakobsen, Marianne Scholze, Alexandra Nybo, Mads Soerensen, Grete Mortensen, Sussie Vejen, Knud Barington, Torben Bistrup, Claus |
author_sort | Assing, Kristian |
collection | PubMed |
description | INTRODUCTION: End‐stage renal disease (ESRD) is associated with increased infectious susceptibility and with reduced vaccine responses consistent with compromised humoral immunity. Whether the compromised humoral immunity is due to reduced antibody diversity (reduced somatic hypermutation [SHM]) or altered germinal center (GC) dynamics is not known. The GC‐derived chemokine CXCL13 as well as peripheral T follicular helper cells (pTFH) reflect GC dynamics, but have, similar to SHM, never been characterized in relation to ESRD. METHODS: Serum CXCL 13 was determined by ELISA. PTFH were flow‐cytometrically defined as CD4(+) CD45RA(−) CCR7(+) CXCR5(+) lymphocytes. Apoptotic lymphocyte subsets were in addition annexin V(+). SHM was determined, by next‐generation sequencing and bioinformatics, as nucleotide mutations within the IgG V(H) (comprising the important antigen‐binding domains of IgG, CDR1, and CDR2). RESULTS: Elevated CXCL13 levels characterized ESRD (n = 19; [median] 90 pg/ml, P < 0.01) (controls, n = 18; 62 pg/ml). ESRD pTFH frequencies (n = 19; 11.6% [of CD4(+) memory T cells], P < 0.02*, *Bonferroni corrected) (controls, n = 22; 14.9%) and concentrations (n = 19; 0.03 × 10(9)/L, P < 0.02*) (controls, n = 22; 0.07 × 10(9)/L) were reduced. ESRD pTFH were more apoptotic (n = 9; 25.7%, P = 0.04*) (controls, n = 10; 15.9%). SHM did not discriminate between ESRD (n = 10; 7.4%, P = 0.21) and controls (n = 10; 8.4%). CONCLUSIONS: Elevated CXCL13 levels, reduced pTFH levels, and increased pTFH apoptosis suggest that perturbed GC dynamics, and not reduced antibody diversity, underlie the diminished vaccine responses and the compromised humoral immunity in ESRD. However, largely preserved SHM provides a rationale for pursuing vaccination in relation to ESRD. |
format | Online Article Text |
id | pubmed-4879468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48794682016-12-12 Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease Assing, Kristian Nielsen, Christian Jakobsen, Marianne Scholze, Alexandra Nybo, Mads Soerensen, Grete Mortensen, Sussie Vejen, Knud Barington, Torben Bistrup, Claus Immun Inflamm Dis Original Research INTRODUCTION: End‐stage renal disease (ESRD) is associated with increased infectious susceptibility and with reduced vaccine responses consistent with compromised humoral immunity. Whether the compromised humoral immunity is due to reduced antibody diversity (reduced somatic hypermutation [SHM]) or altered germinal center (GC) dynamics is not known. The GC‐derived chemokine CXCL13 as well as peripheral T follicular helper cells (pTFH) reflect GC dynamics, but have, similar to SHM, never been characterized in relation to ESRD. METHODS: Serum CXCL 13 was determined by ELISA. PTFH were flow‐cytometrically defined as CD4(+) CD45RA(−) CCR7(+) CXCR5(+) lymphocytes. Apoptotic lymphocyte subsets were in addition annexin V(+). SHM was determined, by next‐generation sequencing and bioinformatics, as nucleotide mutations within the IgG V(H) (comprising the important antigen‐binding domains of IgG, CDR1, and CDR2). RESULTS: Elevated CXCL13 levels characterized ESRD (n = 19; [median] 90 pg/ml, P < 0.01) (controls, n = 18; 62 pg/ml). ESRD pTFH frequencies (n = 19; 11.6% [of CD4(+) memory T cells], P < 0.02*, *Bonferroni corrected) (controls, n = 22; 14.9%) and concentrations (n = 19; 0.03 × 10(9)/L, P < 0.02*) (controls, n = 22; 0.07 × 10(9)/L) were reduced. ESRD pTFH were more apoptotic (n = 9; 25.7%, P = 0.04*) (controls, n = 10; 15.9%). SHM did not discriminate between ESRD (n = 10; 7.4%, P = 0.21) and controls (n = 10; 8.4%). CONCLUSIONS: Elevated CXCL13 levels, reduced pTFH levels, and increased pTFH apoptosis suggest that perturbed GC dynamics, and not reduced antibody diversity, underlie the diminished vaccine responses and the compromised humoral immunity in ESRD. However, largely preserved SHM provides a rationale for pursuing vaccination in relation to ESRD. John Wiley and Sons Inc. 2016-05-25 /pmc/articles/PMC4879468/ /pubmed/27957330 http://dx.doi.org/10.1002/iid3.108 Text en © 2016 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Assing, Kristian Nielsen, Christian Jakobsen, Marianne Scholze, Alexandra Nybo, Mads Soerensen, Grete Mortensen, Sussie Vejen, Knud Barington, Torben Bistrup, Claus Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease |
title | Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease |
title_full | Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease |
title_fullStr | Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease |
title_full_unstemmed | Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease |
title_short | Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease |
title_sort | evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end‐stage renal disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879468/ https://www.ncbi.nlm.nih.gov/pubmed/27957330 http://dx.doi.org/10.1002/iid3.108 |
work_keys_str_mv | AT assingkristian evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT nielsenchristian evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT jakobsenmarianne evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT scholzealexandra evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT nybomads evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT soerensengrete evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT mortensensussie evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT vejenknud evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT baringtontorben evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease AT bistrupclaus evidenceofperturbedgerminalcenterdynamicsbutpreservedantibodydiversityinendstagerenaldisease |